Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso) in Subjects With Pulmonary Arterial Hypertension

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso) in Subjects With Pulmonary Arterial Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esuberaprost (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms BEAT
  • Sponsors Lung Biotechnology
  • Most Recent Events

    • 29 Apr 2019 Status changed from discontinued to completed.
    • 08 Apr 2019 Status changed from active, no longer recruiting to discontinued because Beat study did not meet its primary endpoint of delayed time to first clinical worsening event, so company has decided to discontinue further esuberaprost development, according to a United Therapeutics Corporation media release.
    • 08 Apr 2019 According to a United Therapeutics Corporation media release, primary endpoint (Time to clinical worsening defined as time from randomization to the first of any of the events described below) has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top